ArticleAnnals of laboratory medicine2018
Delamanid, Bedaquiline, and Linezolid Minimum Inhibitory Concentration Distributions and Resistance-related Gene Mutations in Multidrug-resistant and Extensively Drug-resistant Tuberculosis in Korea.
Article in Annals of laboratory medicine, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 34 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed, 4 syntheses or guidelines pooled it, 73 citations in OpenAlex.
- Global mapping of bedaquiline-resistant Mycobacterium tuberculosis: a systematic review.BMC infectious diseases · 2026Pooled it
- Epidemiology of extensively drug-resistant tuberculosis among patients with multidrug-resistant tuberculosis: A systematic review and meta-analysis.International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases · 2023Pooled it
- Linezolid resistance in multidrug-resistant mycobacterium tuberculosis: A systematic review and meta-analysis.Frontiers in pharmacology · 2022Pooled it
- Genetic variants and their association with phenotypic resistance to bedaquiline inThe Lancet. Microbe · 2021Pooled it
- Treatment of Highly Drug-Resistant Pulmonary Tuberculosis.The New England journal of medicine · 2020Trial
- Rare emergence of delamanid resistance in multidrug-/rifampicin-resistant tuberculosis patients receiving delamanid-containing regimens: a prospective multicentric study in China.Annals of clinical microbiology and antimicrobials · 2026Article
- Whole-Genome and Targeted Sequencing of 75 Drug-ResistantAnnals of laboratory medicine · 2026Article
- Molecular Mechanisms of Resistance and Treatment Efficacy of Delamanid AgainstHealth science reports · 2026Review
- Implementation of sequencing-based surveillance for drug-resistant tuberculosis in Nigeria.Frontiers in tuberculosis · 2026Article
- Investigation of delamanid, bedaquiline, and linezolid resistance rates and related gene mutations in multidrug-resistant Mycobacterium tuberculosis in regional tuberculosis reference laboratories of Iran.BMC microbiology · 2025Article
- ThePeerJ · 2025Review
- A Narrative Review of Bedaquiline and Delamanid: New Arsenals Against Multidrug-Resistant and Extensively Drug-Resistant Mycobacterium tuberculosis.Journal of clinical laboratory analysis · 2024Review
- Article
- Spontaneous mutational patterns and novel mutations for bedaquiline and clofazimine resistance inMicrobiology spectrum · 2023Article
- Bedaquiline, Delamanid, Linezolid, Clofazimine, and Capreomycin MIC Distributions for Drug ResistanceInfection and drug resistance · 2023Article
- Mutations and insights into the molecular mechanisms of resistance of Mycobacterium tuberculosis to first-line.Genetics and molecular biology · 2023Article
- Mutations inAntimicrobial agents and chemotherapy · 2022Article
- Evaluation of the broth microdilution plate methodology for susceptibility testing of Mycobacterium tuberculosis in Peru.BMC infectious diseases · 2022Article
- Delamanid or pretomanid? A Solomonic judgement!The Journal of antimicrobial chemotherapy · 2022Article
- MDR Tuberculosis Treatment.Medicina (Kaunas, Lithuania) · 2022Review
Corrections and comments
- Erratum issued
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundDelamanid, bedaquiline, and linezolid have recently been approved for the treatment of multidrug- and extensively drug-resistant (MDR and XDR, respectively) tuberculosis (TB). To use these drugs effectively, drug susceptibility tests, including rapid molecular techniques, are required for accurate diagnosis and treatment. Furthermore, mutation analyses are needed to assess the potential for resistance. We evaluated the minimum inhibitory concentrations (MICs) of these three anti-TB drugs for Korean MDR and XDR clinical strains and mutations in genes related to resistance to these drugs.
methodsMICs were determined for delamanid, bedaquiline, and linezolid using a microdilution method. The PCR products of drug resistance-related genes from 420 clinical Mycobacterium tuberculosis strains were sequenced and aligned to those of M. tuberculosis H37Rv.
resultsThe overall MICs for delamanid, bedaquiline, and linezolid ranged from ≤0.025 to >1.6 mg/L, ≤0.0312 to >4 mg/L, and ≤0.125 to 1 mg/L, respectively. Numerous mutations were found in drug-susceptible and -resistant strains. We did not detect specific mutations associated with resistance to bedaquiline and linezolid. However, the Gly81Ser and Gly81Asp mutations were associated with resistance to delamanid.
conclusionsWe determined the MICs of three anti-TB drugs for Korean MDR and XDR strains and identified various mutations in resistance-related genes. Further studies are needed to determine the genetic mechanisms underlying resistance to these drugs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.